Edition:
United Kingdom

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

9.27USD
19 Jan 2018
Change (% chg)

$-0.06 (-0.64%)
Prev Close
$9.33
Open
$9.36
Day's High
$9.52
Day's Low
$9.15
Volume
67,015
Avg. Vol
80,239
52-wk High
$24.00
52-wk Low
$8.40

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING.SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019.  Full Article

Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY.SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018.  Full Article

Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN.SELECTA BIOSCIENCES INC - CEO WERNER CAUTREELS PLANS RETIREMENT AT END OF 2018.SELECTA BIOSCIENCES INC - OMID FAROKHZAD APPOINTED CHAIRMAN OF BOARD.SELECTA BIOSCIENCES INC - EXPECTS CAUTREELS TO REMAIN A MEMBER OF BOARD FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences announces Q3 loss per share $0.66
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces third quarter 2017 financial results and provides corporate update.Q3 revenue $100,000 versus $1.0 million.Q3 revenue view $383,000 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.66.Selecta -‍ Cash, cash equivalents, short-term deposits, investments & restricted cash sufficient to fund expenditure requirements into mid-2019​.  Full Article

Selecta Biosciences names John Leaman chief financial officer
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces important additions to senior leadership team.Selecta Biosciences Inc - ‍Appointment of John Leaman as company's new chief financial officer and head of corporate strategy​.  Full Article

Selecta Biosciences Q2 loss per share $2.75
Tuesday, 9 Aug 2016 

Selecta Biosciences Inc : Selecta biosciences announces second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S .Q2 revenue $2.0 million versus I/B/E/S view $1.7 million.  Full Article

Selecta Biosciences IPO of 5 mln shares priced at $14 per share
Wednesday, 22 Jun 2016 

Selecta Biosciences Inc : Says initial public offering of 5.00 million common shares priced at $14.00per share .Selecta Biosciences announces pricing of initial public offering.  Full Article

Selecta Biosciences sees IPO of 4.25 mln shares
Monday, 20 Jun 2016 

Selecta Biosciences Inc : Sees IPO of 4.25 mln shares of common stock priced to be between $14.00 and $16.00 per share-SEC filing . Intends to use about $23 million of IPO proceeds to support clinical development and manufacturing scale-up of SEL-212 .Intends to use about $10 million of proceeds to fund start of phase 1 clinical trial, manufacturing scale-up of first gene therapy program.  Full Article

BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018

* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING